Optimizing Management in IBD: Challenging Cases

The Gastroenterology Learning Pathway, Phase III: Achieving Success in IBD Management
0.75 AMA PRA Category 1 Credit(s)
Launch Date:
December 26, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Gastroenterologists and gastroenterology NPs and PAs

Relevant Terms:

Gastroenterology, IBD

Gil Y. Melmed, MD, MS (Chair)

Gil Y. Melmed, MD, MS
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Gil Y. Melmed, MD, MS, is the co-director of the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in Los Angeles, CA. He earned his medical degree from Albert Einstein College of Medicine in the Bronx, NY and a Master of Science degree in clinical research from UCLA School of Medicine in Los Angeles, CA. He completed his gastroenterology fellowship at the University of California, Los Angeles, CA. Dr Melmed is board certified in gastroenterology.

Dr Melmed’s research interests include clinical outcomes and quality of care in inflammatory bowel disease (IBD). He has authored or coauthored more than 130 articles in peer-reviewed journals and several book chapters. He has been an associate editor of the American Journal of Gastroenterology, an ad hoc reviewer for several journals, and a clinical research editor for Inflammatory Bowel Diseases. Dr Melmed has given more than 100 invited presentations nationally and internationally. He is a committee member of several professional organizations, including the American Gastroenterology Association, the American College of Gastroenterology and the Crohn’s and Colitis Foundation, where he serves as co-chair of the IBD Quality of Care committee. He has led or participated in the development of quality measures for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, and the Canadian Crohn’s and Colitis organizations.

Adam S. Cheifetz, MD

Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Adam S. Cheifetz, MD, is the director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and an associate professor of Medicine at Harvard Medical School in Boston, MA. Dr Cheifetz is also the director of the Harvard Medical School Gastroenterology Clerkship Elective and assistant director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center. Dr Cheifetz received his medical degree from Weill Medical College of Cornell University in New York, NY and completed his residency and fellowship at Yale – New Haven Hospital in New Haven, CT.

Dr Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases (IBD). In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 150 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies. Dr Cheifetz lectures nationally and internationally on IBD. In addition, he serves on numerous editorial boards, including Inflammatory Bowel Diseases, Journal of Crohn’s and Colitis, and the World Journal of Gastroenterology.

Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the
  University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Gary R. Lichtenstein, MD, FACP, FACG, AGAF, is the director of the Inflammatory Bowel Disease Center and a professor of medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, PA. Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine in New York, NY. He then completed his internship and residency in internal medicine at Duke University Medical Center in Durham, NC. He also served a fellowship in gastroenterology at the Hospital of the University of Pennsylvania of the University of Pennsylvania School of Medicine.

Dr Lichtenstein’s current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn’s disease, including a significant focus on the safety of current and future medical therapy. He has also focused his research on the natural history of disease. Dr Lichtenstein has received numerous research grants and has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn’s disease.

Dr Lichtenstein is a fellow of the American Gastroenterological Association, the American College of Physicians, and the American College of Gastroenterology, has been listed in “Best Doctors in America” (inflammatory bowel disease), and has served as medical secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds membership and committee positions in many professional societies at a national level.

Dr Lichtenstein has served on the editorial board of many journals, including Gastroenterology, American Journal of Gastroenterology, Inflammatory Bowel Diseases, World Journal of Gastroenterology, and Digestive Diseases and Science. He is the author or coauthor of more than 325 peer-reviewed primary articles and chapters and has presented over 250 abstracts and edited 18 books. He has lectured at a national and an international level at over 500 invited conferences, lectures, symposiums, and institutional grand rounds.

1. Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
2. Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity 
3. Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
4. Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making 


The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees), Pfizer (Research).
  • Adam S. Cheifetz, MD, has affiliations with AbbVie, Arena, Ferring, Janssen, Pfizer, Samsung, Takeda (Consulting Fees); Miraca (Grant/Research Support).
  • Gary R. Lichtenstein, MD, FACP, FACG, AGAF, has affiliations with Abbott Corporation/AbbVie, Celgene, CellCeutrix, Ferring, Gilead, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Shire, Takeda, UCB (Consulting Fees); Celgene, Janssen Orthobiotech, Salix Pharmaceuticals, Shire, UCB (Research); Luitpold/American Regent, Merck, Romark (Other Financial Benefit).  

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Estimated time to complete: 0.75 hour
Medium: Internet

There is no fee for this educational activity.

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.


*The expense for this gift card is solely funded by RMEI Medical Education.  No supporter funding was used for the expense of this gift card.​

Rules and Regulations  
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.




Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above